We are always evolving in an ever-changing industry.

New England Journal of Medicine publishes phase 3 PATINA trial data demonstrating a significant progression-free survival benefit with palbociclib in metastatic HR+, HER2+ breast cancer

PrECOG, LLC, collaborated with global partners on the first large, randomized phase 3 study to show a clinical benefit for CDK4/6 inhibition in HR+, HER2+ metastatic disease, resulting in a 15-month improvement in progression-free survival Philadelphia, PA, January 29, 2026 — PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 […]